Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer

Y. Wan, B. Liu, H. Lei, B. Zhang, Y. Wang, H. Huang, S. Chen, Y. Feng, L. Zhu, Y. Gu, Q. Zhang, H. Ma, S. Y. Zheng

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Background: The comparison between relatively intact nanoscale extracellular vesicle-derived DNA (nEV-DNA) and fragmented circulating cell-free DNA (cfDNA) in mutation detection among patients with non-small-cell lung cancer (NSCLC) has not been carried out yet, and thus deserves investigation. Patients and methods: Both nEV-DNA and cfDNA was obtained from 377 NSCLC patients with known EGFR mutation status and 69 controls. The respective EGFRE19del/T790M/L858R mutation status was interrogated with amplification-refractory-mutation-system-based PCR assays (ARMS-PCR). Results: Neither nEV-DNA nor cfDNA levels show a strong correlation with tumor volumes. There is no correlation between cfDNA and nEV-DNA levels either. The detection sensitivity of nEV-DNA and cfDNA using ARMS-PCR in early-stage NSCLC was 25.7% and 14.2%, respectively, with 96.6% and 91.7% specificity, respectively. In late-stage NSCLC, both nEV-DNA and cfDNA show 80% sensitivity and over 95% specificity. Conclusions: nEV-DNA is superior to cfDNA for mutation detection in early-stage NSCLC using ARMS-PCR. However, the advantages vanish in late-stage NSCLC.

Original languageEnglish (US)
Pages (from-to)2379-2383
Number of pages5
JournalAnnals of Oncology
Volume29
Issue number12
DOIs
StatePublished - Dec 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this